Loukianos Rallidis Selected Research

Glucose (Dextrose)

1/2017	Evaluating the glucose raising effect of established loci via a genetic risk score.
1/2014	Effect of green tea on postprandial antioxidant capacity, serum lipids, C-reactive protein and glucose levels in patients with coronary artery disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Loukianos Rallidis Research Topics

Disease

5	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 09/2008
4	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 01/2016
3	Hypertension (High Blood Pressure) 12/2022 - 08/2009
2	Hypercholesterolemia 01/2023 - 01/2016
2	Myocardial Infarction 07/2022 - 07/2012
2	Coronary Artery Disease (Coronary Atherosclerosis) 12/2020 - 01/2014
1	Obesity 01/2024
1	Hypertriglyceridemia 01/2023
1	Peripheral Arterial Disease 07/2022
1	Urologic Neoplasms (Urological Cancer) 01/2022
1	Chronic Limb-Threatening Ischemia 12/2020
1	Overweight 12/2020
1	Atherosclerosis 12/2020
1	Multiple Sclerosis 01/2020
1	Pulmonary Arterial Hypertension 01/2020
1	Dyslipidemias (Dyslipidemia) 07/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2018
1	Genetic Risk Score 01/2017
1	Thrombosis (Thrombus) 03/2016
1	Chronic Renal Insufficiency 01/2016
1	Coronary Disease (Coronary Heart Disease) 11/2013

Drug/Important Bio-Agent (IBA)

4	LipidsIBA 01/2024 - 01/2014
4	oxidized low density lipoproteinIBA 01/2023 - 01/2016
3	Triglycerides (Triacylglycerol)IBA 01/2023 - 01/2018
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2022 - 07/2012
2	HDL CholesterolIBA 12/2022 - 12/2020
2	LDL CholesterolIBA 12/2021 - 05/2020
2	TeaIBA 05/2019 - 01/2014
2	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 01/2014
1	omega-Chloroacetophenone (Mace)IBA 07/2022
1	Lipoprotein(a)IBA 01/2022
1	VitaminsIBA 12/2020
1	InterferonsIBA 01/2020
1	CholesterolIBA 07/2019
1	Endothelial Protein C ReceptorIBA 03/2016
1	Proprotein Convertase 9IBA 01/2016
1	Ezetimibe (Zetia)FDA Link 01/2016
1	evolocumabIBA 01/2016
1	alirocumabIBA 01/2016
1	PCSK9 InhibitorsIBA 01/2016
1	AntioxidantsIBA 01/2014
1	C-Reactive ProteinIBA 01/2014
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 11/2013
1	Protease Inhibitors (Protease Inhibitor)IBA 09/2008

Therapy/Procedure

2	Therapeutics 01/2020 - 08/2009
1	Drug Therapy (Chemotherapy) 01/2022
1	Nutritional Support (Artificial Feeding) 12/2020
1	Mediterranean Diet 09/2018
1	Percutaneous Coronary Intervention 07/2012